Azimilide dihydrochloride, a novel antiarrhythmic agent

The American Journal of Cardiology
R KaramA Moore

Abstract

Azimilide, a novel class III antiarrhythmic agent, blocks both the slowly activating (IKs) and rapidly activating (IKr) components of the delayed rectifier potassium current, which distinguishes it from conventional potassium channel blockers such as sotalol and dofetilide, which block only IKr. Azimilide is being developed to prolong the time to recurrence of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia in patients with and without structural heart disease. Azimilide is also being studied for its role in prevention of sudden cardiac death in high-risk patients after myocardial infarction (MI). Preclinical and clinical studies indicate that azimilide prolongs cardiac refractory period in a dose-dependent manner, as manifested by increases in action potential duration, QTc interval, and effective refractory period. Azimilide does not affect PR or QRS interval and minimally affects hemodynamic properties such as blood pressure and heart rate. Its in vivo effects appear to be rate-independent and are maintained under ischemic or hypoxic conditions, properties of potential clinical significance. Azimilide has shown excellent efficacy (>85%) in suppressing supraventricular arrhythmias in a variety...Continue Reading

References

Jul 1, 1996·Journal of Cardiovascular Electrophysiology·M RestivoN el-Sherif

❮ Previous
Next ❯

Citations

Nov 26, 2002·British Journal of Clinical Pharmacology·Alfred E CoreyGary A Thompson
Mar 25, 1999·Journal of Cardiovascular Electrophysiology·A J Camm, Y G Yap
Aug 13, 2004·Current Cardiology Reports·Deborah L Wolbrette
Oct 7, 2000·Clinical and Experimental Pharmacology & Physiology·H J Witchel, J C Hancox
Jan 24, 2003·Annual Review of Pharmacology and Toxicology·Colleen E ClancyRobert S Kass
Feb 14, 2002·Clinical Cardiology·Deborah WolbretteAlan Kadish
Jul 30, 2005·Journal of Pharmaceutical Sciences·P RileyT J Moorehead
Jun 10, 2008·Cardiology Clinics·L Brent Mitchell
Jun 14, 2005·Journal of Clinical Pharmacology·Roger D ToothakerJames H Powell
Nov 26, 2004·British Journal of Clinical Pharmacology·Mohamed El MouelhiGary A Thompson
Mar 31, 2004·Journal of Clinical Pharmacology·Mohamed El MouelhiGary A Thompson
Nov 4, 2000·Expert Opinion on Investigational Drugs·R Abrol, R L Page
Feb 28, 2003·Expert Opinion on Investigational Drugs·Jan Nemec, Win-Kuang Shen
Jul 11, 2000·Japanese Journal of Pharmacology·J Tamargo
Apr 4, 2017·International Journal of Cardiology·A John Camm
Dec 20, 2002·Journal of Cardiovascular Pharmacology and Therapeutics·Fuhua ChenThomas S Klitzner
Feb 18, 2004·Circulation·A John CammUNKNOWN AzimiLide post Infarct surVival Evaluation (ALIVE) Investigators
Dec 25, 2004·Physiological Reviews·Colleen E Clancy, Robert S Kass
Dec 20, 2007·Journal of Cardiovascular Pharmacology·Philippe ChevalierQuadiri Timour
Mar 24, 2000·Drugs·D Clemett, A Markham
Dec 26, 2006·Expert Review of Cardiovascular Therapy·Henri Roukoz, Walid Saliba
Feb 10, 2000·Current Opinion in Cardiology·P T Sager
Feb 5, 1999·Current Opinion in Cardiology·D Wolbrette, H Patel
Feb 5, 1999·Current Opinion in Cardiology·P T Sager
Jun 27, 2006·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Lena LöfbergLeif Carlsson
Feb 23, 2000·Journal of Cardiovascular Pharmacology and Therapeutics·T J Colatsky
Aug 23, 2002·Pharmacology & Therapeutics·Alan Wickenden
Jun 27, 2021·European Journal of Pharmacology·Moawiah M Naffaa, Ola A Al-Ewaidat

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.